|1.||Pettit, George R: 4 articles (07/2011 - 02/2004)|
|2.||Pettit, G R: 4 articles (03/2003 - 07/2000)|
|3.||Bibby, M C: 3 articles (03/2003 - 03/2002)|
|4.||Cooper, P A: 3 articles (03/2003 - 03/2002)|
|5.||Lippert, J W: 3 articles (03/2003 - 07/2000)|
|6.||Hamel, Ernest: 2 articles (08/2013 - 07/2011)|
|7.||Lippert, John W: 2 articles (07/2011 - 02/2004)|
|8.||Swaine, David J: 2 articles (10/2004 - 02/2004)|
|9.||Shnyder, S D: 2 articles (03/2003 - 03/2002)|
|10.||Holwell, S E: 2 articles (11/2002 - 03/2002)|
10/01/2004 - "Tumor cells retrieved from combretastatin A1 phosphate-treated mice had a mean G2-M phase population of 36.3% (i.p.) and 29.36% (s.c.) compared with cells retrieved from vehicle group mice (5.58 and 5.49%, respectively; P = <0.001). "
11/01/2002 - "In summary, combretastatin A-1 phosphate can exert its anti-tumor action via an anti-vascular mechanism. "
11/01/2002 - "Morphological examination of hepatic deposits of HT29 and DLD-1 human colon tumors in nude mice demonstrated that combretastatin A-1 phosphate displays greater anti-tumor effects than the A-4 analog at the same dose and this order of activity (A-1 > A-4) is mirrored in the subcutaneous site with the same tumor type. "
07/01/2000 - "Both diols, (R,R)-6 and (S, S)-7, displayed less cancer cell growth inhibition and less antibiotic activity than did natural combretastatin A-1 (1a) (P-388 ED(50) 0.25 microg/mL)."
01/01/2015 - "The natural stilbenoids combretastatin A-4 (CA4) and combretastatin A-1 (CA1) are potent antitubulin agents demonstrating antimitotic activity as well as tumor vascular disruption property. "
11/01/2002 - "Treatment of a well-vascularised murine colon adenocarcinoma (MAC 29) with an effective dose (150 mg/kg) of combretastatin A-1 phosphate resulted in a dramatic decrease in functional vascular volume 2 hours after administration. "
03/01/2003 - "Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model."
|3.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
|4.||Colorectal Neoplasms (Colorectal Cancer)
06/09/2015 - "We aimed to test the ability of texture analysis to differentiate the spatial heterogeneity of (125)I-A5B7 anti-carcinoembryonic antigen antibody distribution by nano-single photon emission computed tomography (SPECT) in well-differentiated (SW1222) and poorly differentiated (LS174T) hepatic metastatic colorectal cancer models before and after combretastatin A1 di-phosphate anti-vascular therapy. "
|5.||Neoplasm Metastasis (Metastasis)
|1.||combretastatin A-4 (combretastatin A4)